Drug discovery is a high risk, high return business. Despite the intrinsic risks, pharma companies continue to invest heavily in R&D to improve the quality of life of patients in needs of treatment. While capital is important in R&D outcomes, innovation-based organisations need to understand the best model to adopt to speed up the process in bringing discoveries to useful commercial …
